Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 700Lung Neoplasms 298Small Cell Lung Carcinoma 149Colorectal Neoplasms 114Melanoma 106Neoplasms 93Breast Neoplasms 93Ovarian Neoplasms 92Neoplasm Metastasis 86Squamous Cell Carcinoma of Head and Neck 83Stomach Neoplasms 81Pancreatic Neoplasms 79Carcinoma, Renal Cell 66Triple Negative Breast Neoplasms 63Esophageal Neoplasms 51Endometrial Neoplasms 48Uterine Cervical Neoplasms 47Head and Neck Neoplasms 47Mesothelioma 42Mesothelioma, Malignant 41Sarcoma 40Prostatic Neoplasms 36Urinary Bladder Neoplasms 34Colonic Neoplasms 32Carcinoma, Transitional Cell 32Carcinoma, Hepatocellular 31Adenocarcinoma of Lung 31Carcinoma 26Recurrence 21Thyroid Neoplasms 20

Interventions

osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Non-Small Cell Lung Cancer With EGFR Mutation × Thoracic × Clear all
NCT06306456 2024-07-08

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Suzhou Genhouse Bio Co., Ltd.

Phase 1/2 Recruiting
94 enrolled
Thoracic

Non-Small Cell Lung Cancer With EGFR Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡